These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 27115884

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. FDG PET/CT and MRI Features of Pathologically Proven Schwannomas.
    Dewey BJ, Howe BM, Spinner RJ, Johnson GB, Nathan MA, Wenger DE, Broski SM.
    Clin Nucl Med; 2021 Apr 01; 46(4):289-296. PubMed ID: 33443952
    [Abstract] [Full Text] [Related]

  • 3. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.
    Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, Phelps ME, Weber WA, Eilber FC.
    Cancer; 2010 Jan 15; 116(2):451-8. PubMed ID: 19924789
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. CT, MRI, and 18F-FDG PET/CT findings of malignant peripheral nerve sheath tumor of the head and neck.
    Kim HY, Hwang JY, Kim HJ, Kim YK, Cha J, Park GM, Kim ST.
    Acta Radiol; 2017 Oct 15; 58(10):1222-1230. PubMed ID: 28068826
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
    Karabatsou K, Kiehl TR, Wilson DM, Hendler A, Guha A.
    Neurosurgery; 2009 Oct 15; 65(4 Suppl):A160-70. PubMed ID: 19927062
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
    Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjayanathan V, O'Doherty M.
    Ann Oncol; 2008 Feb 15; 19(2):390-4. PubMed ID: 17932395
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Correlations between F-18 FDG PET/CT and pathological findings in soft tissue lesions.
    Nose H, Otsuka H, Otomi Y, Terazawa K, Takao S, Iwamoto S, Harada M.
    J Med Invest; 2013 Feb 15; 60(3-4):184-90. PubMed ID: 24190034
    [Abstract] [Full Text] [Related]

  • 19. Diagnostic value of 18F-FDG PET-CT in detecting malignant peripheral nerve sheath tumors among adult and pediatric neurofibromatosis type 1 patients.
    Geitenbeek RTJ, Martin E, Graven LH, Broen MPG, Anten MHME, van der Pol JAJ, Verhoef C, Taal W.
    J Neurooncol; 2022 Feb 15; 156(3):559-567. PubMed ID: 35025020
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.